VYN 201
Alternative Names: TAY-B1; VYN-201Latest Information Update: 06 Sep 2024
Price :
$50 *
At a glance
- Originator In4Derm
- Developer Tay Therapeutics; VYNE Therapeutics
- Class Anti-inflammatories; Antifibrotics; Antirheumatics; Skin disorder therapies; Small molecules
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Vitiligo
- Preclinical Idiopathic pulmonary fibrosis; Inflammation; Rheumatoid arthritis; Skin disorders